SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about disclosure

23 Apr 2026 Evaluate

Pursuant to the provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, Cipla has informed that the Cipla USA Inc., wholly owned subsidiary of the Company in USA (referred as ‘Cipla’) has received final approval from the United States Food and Drug Administration (‘USFDA’) for the Abbreviated New Drug Application (‘ANDA’) submitted for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline. Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise induced bronchospasm in patients aged four years and older. The product is expected to be launched in H1 of FY 2026-27 in the United States of America. A press release dated 23rd April 2026 is also enclosed.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1294.75 -11.10 (-0.85%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×